Barclays’s Albireo Pharma Inc ALBO Stock Holding History

Barclays’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-4,500	Closed	-$270K	–	7763
2013 Q4	$270K	Sell	4,500 -8,333	-65%	-$611K	﹤0.01%	4705
2013 Q3	$1.16M	Buy	+12,833	New	+$1.67M	﹤0.01%	3198

Other funds holding ALBO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's ALBO Position: Q1 2023 in Review

Barclays sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 6,163 shares — an estimated $133K sold.

Barclays first reported a position in ALBO in Q2 2013 and held it in 22 quarters. The position peaked at $637K in Q1 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

Barclays reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
Barclays sold 6,163 Albireo Pharma Inc shares in Q1 2023, an estimated $133K.
Barclays first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 22 quarters.
Barclays's Albireo Pharma Inc position peaked at $637K in Q1 2021.
3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.